April 15 (Reuters) - Zhaojin Capital: RECEIVED CHINESE REGULATORY APPROVALS IN RESPECT OF TIETTO OFFER (([email protected];))
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status